Abstract Number: 1105 • 2015 ACR/ARHP Annual Meeting
The IgG/IgG4 mRNA Ratio By Quantitative PCR Accurately Diagnoses IgG4-Related Disease and Predicts Treatment Response
Background/Purpose : IgG4-associated cholangitis (IAC) and autoimmune pancreatitis (AIP) are major manifestations of IgG4-related disease (IRD). Misdiagnosis and inadequate treatment are common since IAC and…Abstract Number: 1106 • 2015 ACR/ARHP Annual Meeting
Efficacy of Abbv-105, a Selective and Irreversible Inhibitor of Bruton’s Tyrosine Kinase (BTK), in Multiple Models of Inflammation
Background/Purpose: Bruton’s Tyrosine Kinase (BTK) is a non-receptor tyrosine kinase required for intracellular signaling pathways downstream of several key immunoreceptors, including the B cell receptor,…Abstract Number: 1107 • 2015 ACR/ARHP Annual Meeting
Inhibition of B Cell Activation and Plasma Cell Differentiation By Epratuzumab, a Humanized Monoclonal Antibody Targeting CD22
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by B cell hyperactivity and production of autoantibodies. Treatment of patients with moderate-to-severe SLE with epratuzumab, a humanized…Abstract Number: 1108 • 2015 ACR/ARHP Annual Meeting
Epratuzumab, a Monoclonal Antibody Targeting CD22 on B Cells, Stimulates the Phosphorylation of Upstream Inhibitory Signals of the B Cell Receptor
Background/Purpose: Epratuzumab, a humanized monoclonal antibody targeting CD22, is currently in phase 3 clinical trials in patients with systemic lupus erythematosus (SLE). Previous work suggests…Abstract Number: 1109 • 2015 ACR/ARHP Annual Meeting
Co-Crystal Structure of TACI and APRIL-BAFF-BAFF Heteromer Suggests That Charged Residues in APRIL and BAFF Dictate Their Receptor Binding Affinities
Background/Purpose: The human B cell survival factor, B cell activation factor (BAFF), and its closely related homologue, a proliferation-inducing ligand (APRIL), modulate B cell functions…Abstract Number: 1110 • 2015 ACR/ARHP Annual Meeting
A Proliferative Inducing Ligand (APRIL) Promotes IL-10 Production of Human B Cells
Background/Purpose: B cells may have a negative regulatory role, mainly mediated by interleukin 10 (IL-10). We recently showed that regulatory B-cell functions are impaired in…Abstract Number: 1111 • 2015 ACR/ARHP Annual Meeting
Relapse of Lupus after B-Cell Depletion Therapy Is Associated with Loss of Apoptotic Cell Clearance and Elevated Type I Interferon Responses in Lupus Prone BXD2
Background/Purpose: B-cell depletion therapy (BCDT) is a promising therapy for autoimmune diseases but relapse can occur. In rheumatoid arthritis, patients who did not respond well…Abstract Number: 1112 • 2015 ACR/ARHP Annual Meeting
Obinutuzumab Outperforms Rituximab at Inducing B-Cell Cytotoxicity in Vitro through Fc-Mediated Effector Mechanisms in Rheumatoid Arthritis and Systemic Lupus Erythematosus
Background/Purpose: Obinutuzumab (OBZ, a Type II anti-CD20 monoclonal antibody [mAb] with afucosylated Fc portion and enhanced affinity for Fcγ receptor III) is more efficient than…Abstract Number: 1113 • 2015 ACR/ARHP Annual Meeting
B Cell Signature Profiling in Systemic Lupus Erythematosus Patients on Belimumab
Background/Purpose: The B cell pool is composed of subsets with different phenotypes and functions that mainly have effector functions to maintain immunologic tolerance. These…Abstract Number: 1114 • 2015 ACR/ARHP Annual Meeting
Profiling Circulating Plasmablasts from Anti-Ro Positive Mothers of Children with Congenital Heart Block to Identify Antigenic Targets Conferring Pathogenicity
Background/Purpose: Neonatal lupus (NL) is an uncommon autoimmune disease classically manifest as permanent complete heart block and/or transient cutaneous lesions. By definition of NL, there…Abstract Number: 1115 • 2015 ACR/ARHP Annual Meeting
B Cell-Intrinsic Interferon Gamma Signals Promote the Development of Systemic Lupus Erythematosus By Enhancing the Formation of Spontaneous Autoimmune Germinal Centers
Background/Purpose: Type 1 interferon (IFN) is strongly implicated in lupus pathogenesis, and SLE patients frequently express a “type 1 IFN gene signature”. The type 2…Abstract Number: 1116 • 2015 ACR/ARHP Annual Meeting
Decreased Expression of Negative Regulators of Toll-like Receptor Signaling and Increased TLR7 Responsiveness in Expanded IgD- CD27- B Cells from Systemic Lupus Erythematosus Patients
Background/Purpose: B cell homeostasis is perturbed in SLE patients; in particular many patients with active disease have a large expansion of IgD- CD27- B cells…Abstract Number: 1117 • 2015 ACR/ARHP Annual Meeting
The B Cell Survival Cytokine BAFF Promotes Systemic Lupus Erythematosus Via Activation of TACI, Not BAFF Receptor
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by polyclonal B cell activation and production of class-switched antinuclear antibodies (ANA). Transgenic mice…Abstract Number: 1118 • 2015 ACR/ARHP Annual Meeting
Role of the Chemokine Receptor CXCR3 in the Function of Regulatory B Cells in Patients with SLE
Background/Purpose: The emerging application of B-cell directed therapies in autoimmune diseases has led to the discovery of a novel B cell population, referred to as…Abstract Number: 1119 • 2015 ACR/ARHP Annual Meeting
High Resolution Motif Mapping of in Situ Anti-Native-Vimentin Antibodies in Lupus Tubulointerstitial Nephritis
Background/Purpose: Severe lupus tubulointerstitial nephritis (TIN) is prognostic of renal failure and characterized by an in situ autoantibody response. By characterizing monoclonal antibodies engineered from…
ACR Meeting Abstracts